Top Five Sharp Business Leaders, Making Their Mark in Industry 2022 - Edition-2-profiles

Novuson Surgical, Inc

4. Stuart Mitchell Founder CEO Novuson Surgical Inc

Novuson is a medical device company that has developed direct therapeutic ultrasound technology to improve surgical outcomes.

Novuson is a medical device company that has developed the only direct therapeutic ultrasound technology to improve surgical outcomes. The University of Washington’s highly reputable Applied Physics Laboratory’s Industrial and Medical Ultrasound Center has been developing Direct Therapeutic Ultrasound (DTU) technology for coagulation and hemostatic control in a spinout, surgical and trauma procedures. DTU technology should enable physicians to perform surgeries more quickly and quickly control the bleeding associated with traumatic injuries.

Direct Therapeutic Ultrasound (DTU) The first significant innovation in advanced energy technology in 25 years Novuson’s patented DTU technology will represent the first significant innovation in 25 years to target hemostasis (bleeding control) in surgical and trauma applications.

Their patented DTU technology will represent the first significant innovation in 25 years to target vessel sealing and dividing, soft tissue ablation, and hemostasis (bleeding control) in surgical and trauma applications without passing an electric current through the patient.

Their Core Values ​​at Novuson Surgical:

  • Team: their most valuable resource.
  • Respect: Respect the diversity and uniqueness of each person.
  • Openness: Everyone has a voice.
  • Dedication: they believe that the devices they develop will improve surgical outcomes and save lives.
  • Quality: their products are of high quality in feeling and work
  • Integrity: Trust, honesty, and the right thing to do.
  • Innovation: they explore possibilities and turn them into useful, meaningful medical device solutions.

Their Devices:

  1. 3mm Ultrastat Mini LS

The smaller the diameter of the surgical instrument, the smaller the incision required, which should result in faster healing and virtually no scarring. In minimally invasive surgery, the smaller the better. Their 3mm Ultrastat LS will be able to seal and split ships up to 7mm.

The world’s first 3mm mini-LS sealer/divider is capable of sealing and splitting vessels up to 7mm. Ergonomically designed to fit and work comfortably in both small and large hands.

  • 5mm Ultrasound LS

For those who prefer 5mm access, their 5mm Ultrastat LS will be able to seal and split ships up to 7mm.  For those who prefer 5mm access, they will offer a 5mm sealer/divider capable of sealing and splitting vessels up to 7mm. Ergonomically designed to fit and work comfortably in both small and large hands.

  • 10mm MAXX

A breakthrough in the management of thick tissue and organ hemostasis. 10mm Ultrasound MAXX should reduce surgical and anesthesia time and reduce blood production consumption, improve patient outcomes, and reduce healthcare costs.

The 10mm Ultrasound MAXX will be capable of hemostasis in tissues up to 50mm thick and will be available in jaw lengths up to 100mm.

Their Technology:

Direct therapeutic ultrasound waves are centered on the plane centered between the opposing jaws, a pattern from the inside out. This therapeutic delivery method should result in no tissue charging, no tissue sticking to the jaw, and no smoke. The ultrasound device transmits direct therapeutic ultrasound, or DTU, embedded in the jaw, transmitting a wide range of tissue thickness and vessel diameter. Ultrasound DTU energy is limited to the width of the jaw and is centered on the mid-plane between the opposing jaws. This results in the use of energy from inside to outside the controlled and uniform therapy coagulation zone without passing an electric current through the patient.

Existing RF solutions rely on the transmission of high-frequency electrical currents by the patient, and “harmonic” solutions rely on the heat of friction through mechanically vibrating cutting bars. Both are severely limited in speed, accuracy, and range of application. Novuson Surgical’s DTU technology has been shown to coagulate tissues quickly and precisely, from delicate vital structures to cross-sections of up to 50 mm thick limbs. This is accomplished without electric current to the patient. This level of performance is unprecedented and disruptive for its market.

Conclusion

The company’s core value is delivering superior clinical performance for a presently unsatisfied clinical category of coagulation and rapid hemostatic control for surgical procedures. Novuson’s robust sealer/divider technology and hemostatic control will become the new standard in surgery with greater efficacy, and lower cost. And improved patient.

 Website- https://novuson.com/

Comment here